Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | geminin | 0.0185 | 0.0785 | 0.0785 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.095 | 0.8865 | 0.5 |
Echinococcus multilocularis | dihydrofolate reductase | 0.1058 | 1 | 1 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0251 | 0.1481 | 0.1481 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.095 | 0.8865 | 0.5 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.095 | 0.8865 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0185 | 0.0785 | 0.0785 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.1058 | 1 | 1 |
Brugia malayi | Dihydrofolate reductase | 0.1058 | 1 | 1 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.095 | 0.8865 | 0.5 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.1058 | 1 | 1 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.1058 | 1 | 1 |
Echinococcus granulosus | dihydrofolate reductase | 0.1058 | 1 | 1 |
Schistosoma mansoni | dihydrofolate reductase | 0.1058 | 1 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.1058 | 1 | 0.5 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.095 | 0.8865 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0185 | 0.0785 | 0.0785 |
Echinococcus multilocularis | geminin | 0.0185 | 0.0785 | 0.0785 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.095 | 0.8865 | 0.5 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.1058 | 1 | 1 |
Onchocerca volvulus | 0.011 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.